Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9UM73: Variant p.Asp1091Asn

ALK tyrosine kinase receptor
Gene: ALK
Feedback?
Variant information Variant position: help 1091 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Aspartate (D) to Asparagine (N) at position 1091 (D1091N, p.Asp1091Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to medium size and polar (N) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In NBLST3; somatic mutation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 1091 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1620 The length of the canonical sequence.
Location on the sequence: help MELQSPEYKLSKLRTSTIMT D YNPNYCFAGKTSSISDLKEV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         MELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEV

Mouse                         MELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEV

Zebrafish                     LELQSPDCKLSKLRASTIMTDYNPNYCFGGKTASVNDLKEV

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 19 – 1620 ALK tyrosine kinase receptor
Topological domain 1060 – 1620 Cytoplasmic
Modified residue 1078 – 1078 Phosphotyrosine
Modified residue 1092 – 1092 Phosphotyrosine
Modified residue 1096 – 1096 Phosphotyrosine
Helix 1087 – 1092



Literature citations
Identification of ALK as a major familial neuroblastoma predisposition gene.
Mosse Y.P.; Laudenslager M.; Longo L.; Cole K.A.; Wood A.; Attiyeh E.F.; Laquaglia M.J.; Sennett R.; Lynch J.E.; Perri P.; Laureys G.; Speleman F.; Kim C.; Hou C.; Hakonarson H.; Torkamani A.; Schork N.J.; Brodeur G.M.; Tonini G.P.; Rappaport E.; Devoto M.; Maris J.M.;
Nature 455:930-935(2008)
Cited for: VARIANTS NBLST3 ASN-1091; ALA-1128; ARG-1166; ASN-1171; ILE-1174; PRO-1192; CYS-1245; VAL-1245; THR-1250 AND GLN-1275;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.